Literature DB >> 19327906

Use of axillary deodorant and effect on acute skin toxicity during radiotherapy for breast cancer: a prospective randomized noninferiority trial.

Valérie Théberge1, François Harel, Anne Dagnault.   

Abstract

PURPOSE: To prospectively determine the effect of deodorant use on acute skin toxicity and quality of life during breast radiotherapy (RT). METHODS AND MATERIALS: Before breast RT, 84 patients were randomly assigned to the deodorant group (n = 40) or the no-deodorant group (n = 44). The patients were stratified by axillary RT and previous chemotherapy. Toxicity evaluations were always performed by the principal investigator, who was unaware of the group assignment, at the end of RT and 2 weeks after completion using the Radiation Therapy Oncology Group acute skin toxicity criteria. Symptoms of acute skin toxicity (i.e., discomfort, pain, pruritus, sweating) and quality of life were self-evaluated. For each criterion, the point estimate of rate difference with the 95% one-sided upper confidence limit was computed. To claim noninferiority owing to deodorant use, the 95% one-sided upper confidence limit had to be lower than the noninferiority margin, fixed to 12.8%.
RESULTS: In the deodorant vs. no-deodorant groups, Grade 2 axillary radiodermatitis occurred in 23% vs. 30%, respectively, satisfying the statistical criteria for noninferiority (p = .019). Grade 2 breast radiodermatitis occurred in 30% vs. 34% of the deodorant vs. no-deodorant groups, respectively, also satisfying the statistical criteria for noninferiority (p = .049). Similar results were observed for the self-reported evaluations. The deodorant group reported less sweating (18% vs. 39%, p = .032). No Grade 3 or 4 radiodermatitis was observed.
CONCLUSION: According to our noninferiority margin definition, the occurrence of skin toxicity and its related symptoms were statistically equivalent in both groups. No evidence was found to prohibit deodorant use (notwithstanding the use of an antiperspirant with aluminum) during RT for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327906     DOI: 10.1016/j.ijrobp.2008.12.046

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.

Authors:  Rebecca K S Wong; René-Jean Bensadoun; Christine B Boers-Doets; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2013-08-14       Impact factor: 3.603

Review 2.  Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Authors:  Victor Y Yazbeck; Liza Villaruz; Marsha Haley; Mark A Socinski
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

3.  The relationship between use of aluminum-containing anti-perspirant and hair color with breast cancer.

Authors:  Maryam Mousavi; Mohammad I Vaghar
Journal:  J Family Med Prim Care       Date:  2021-01-30

Review 4.  Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Raymond Javan Chan; Joan Webster; Bryan Chung; Louise Marquart; Muhtashimuddin Ahmed; Stuart Garantziotis
Journal:  BMC Cancer       Date:  2014-01-31       Impact factor: 4.430

Review 5.  Acute radiation dermatitis in breast cancer patients: challenges and solutions.

Authors:  Adam J Kole; Lauren Kole; Meena S Moran
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-05-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.